Quick Takeaways:
- Viyash Scientific, through its wholly owned subsidiary Alivira Animal Health, has signed a binding agreement to acquire a 100% stake in BioForLife Italia (BFL) for ~$19.7M (~ ₹188 crore).
- Expected to close in Q2 FY27, the acquisition marks Viyash’s strategic entry into Italy, one of Europe’s largest animal health markets, and supports its ambition to expand its global companion animal health business.
- The acquisition will provide Alivira with a platform to introduce products from its companion animal pipeline into Italy while creating opportunities to expand BioForLife’s portfolio across Alivira’s presence in Europe, the Middle East, Asia, and Latin America.
Why It Matters?
Viyash is using BioForLife as a front-end platform to scale its companion animal business in Europe, starting with Italy, one of the continent’s largest and fastest-growing pet health markets.
Market-wise, the all-cash ₹188 crore deal gives Alivira immediate access to BioForLife’s established Italian pet-care franchise in nutraceuticals, pharmaceuticals, and rapid diagnostics, while creating two-way synergies: launching Alivira pipeline products into Italy and pushing BioForLife brands across Alivira’s footprint in Europe, the Middle East, Asia, and Latin America.
Source: NSE
